High‐density lipoprotein functionality and breast cancer: A potential therapeutic target

Samadi, Sara; Mobarhan, Majid Ghayour; Mohammadpour, Amirhooshang; Farjami, Zahra; Tabadkani, Mahla; Hosseinnia, Mohammad; Miri, Mehri; Heydari-majd, Motahareh; Mehramiz, Mehrane; Rezayi, Majid; Rezayi, Majid

doi:10.1002/jcb.27862

Cited by 19 publications

(20 citation statements)

References 107 publications

(344 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are consistent with studies that have shown increased SR-B1 expression in cancer cells, suggesting that during carcinogenesis, tumor cells use HDL to meet their needs for cholesterol [171]. It has been shown that SR-B1 expression is directly proportional to tumor aggressiveness and that tumor progression is reduced by a decrease in SR-B1 activity and expression [169,172]. Diminished HDL-C levels, which are characteristic of cancer, are accompanied by increased expression of SR-B1 [146].…”

Section: Hdl and Cholesterol Trafficking In Crcsupporting

confidence: 90%

Revealing the Role of High-Density Lipoprotein in Colorectal Cancer

Zeljković

Mihajlović

Gojković

et al. 2021

IJMS

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a highly prevalent malignancy with multifactorial etiology, which includes metabolic alterations as contributors to disease development. Studies have shown that lipid status disorders are involved in colorectal carcinogenesis. In line with this, previous studies have also suggested that the serum high-density lipoprotein cholesterol (HDL-C) level decreases in patients with CRC, but more recently, the focus of investigations has shifted toward the exploration of qualitative properties of HDL in this malignancy. Herein, a comprehensive overview of available evidences regarding the putative role of HDL in CRC will be presented. We will analyze existing findings regarding alterations of HDL-C levels but also HDL particle structure and distribution in CRC. In addition, changes in HDL functionality in this malignancy will be discussed. Moreover, we will focus on the genetic regulation of HDL metabolism, as well as the involvement of HDL in disturbances of cholesterol trafficking in CRC. Finally, possible therapeutic implications related to HDL will be presented. Given the available evidence, future studies are needed to resolve all raised issues concerning the suggested protective role of HDL in CRC, its presumed function as a biomarker, and eventual therapeutic approaches based on HDL.

show abstract

Section: Hdl and Cholesterol Trafficking In Crcsupporting

confidence: 90%

Revealing the Role of High-Density Lipoprotein in Colorectal Cancer

Zeljković

Mihajlović

Gojković

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Beyond serum HDL‐cholesterol and apoA1 levels, the composition and functionality of HDL particles has been implicated in the pathophysiology of chronic diseases, including cancer (Andersen, 2018; Andersen and Fernandez, 2013; Navab et al, 2009; Samadi et al, 2019). Variability in HDL profiles may underlie studies that report conflicting associations between HDL‐cholesterol and chronic disease risk (Barter and Rye, 2017; Pirro et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

Low‐Density Lipoproteins, High‐Density Lipoproteins (HDL), and HDL‐Associated Proteins Differentially Modulate Chronic Myelogenous Leukemia Cell Viability

Andersen

Dupree

Murray

et al. 2020

Lipids

View full text Add to dashboard Cite

Cellular lipid metabolism, lipoprotein interactions, and liver X receptor (LXR) activation have been implicated in the pathophysiology and treatment of cancer, although findings vary across cancer models and by lipoprotein profiles. In this study, we investigated the effects of human-derived low-density lipoproteins (LDL), highdensity lipoproteins (HDL), and HDL-associated proteins apolipoprotein A1 (apoA1) and serum amyloid A (SAA) on markers of viability, cholesterol flux, and differentiation in K562 cells-a bone marrow-derived, stem-like erythroleukemia cell model of chronic myelogenous leukemia (CML). We further evaluated whether lipoprotein-mediated effects were altered by concomitant LXR activation. We observed that LDL promoted higher K562 cell viability in a dose-and time-dependent manner and increased cellular cholesterol concentrations, while LXR activation by the agonist TO901317 ablated these effects. LXR activation in the presence of HDL, apoA1 and SAA-rich HDL suppressed K562 cell viability, while robustly inducing mRNA expression of ATP-binding cassette transporter A1 (ABCA1). HDL and its associated proteins additionally suppressed mRNA expression of anti-apoptotic B-cell lymphoma-extra large (BCL-xL), and the erythroid lineage marker 5 0-aminolevulinate synthase 2 (ALAS2), while SAA-rich HDL induced mRNA expression of the megakaryocytic lineage marker integrin subunit alpha 2b (ITGA2B). Together, these findings suggest that lipoproteins and LXR may impact the viability and characteristics of CML cells.

show abstract

“…Alterations in cholesterol pathways such as de novo synthesis, cell internalization, and cholesterol transport mediated by plasmatic lipoproteins could regulate several mechanisms in the development of BC [31]. Very low density lipoproteins (VLDL) and LDL could be critical in several mechanisms of tumor progression [32].…”

Section: Role Of Serum Lipoproteinsmentioning

confidence: 99%

Impact of cholesterol-pathways on breast cancer development, a metabolic landscape

González-Ortiz¹,

Galindo-Hernández²,

Hernández-Acevedo³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

ApoB-lipoproteins and their components modulate intracellular metabolism and have been associated with the development of neoplastic phenomena, such as proliferation, anchorage-independent growth, epithelial-mesenchymal transition, and cancer invasion. In cancer cells, the modulation of targets that regulate cholesterol metabolism, such as synthesis de novo, endocytosis, and oxidation, are contributing factors to cancer development. While mechanisms associated with sterol regulatory element-binding protein 2 (SREBP-2)/mevalonate, the low-density lipoprotein receptor (LDL-R) and liver X receptor (LXR) have been linked with tumor growth; metabolites derived from cholesterol-oxidation, such as oxysterols and epoxy-cholesterols, also have been described as tumor processes-inducers. From this notion, we perform an analysis of the role of lipoproteins, their association with intracellular cholesterol metabolism, and the impact of these conditions on breast cancer development, mechanisms that can be shared during atherogenesis promoted mainly by LDL. Pathways connecting plasma dyslipidemias in conjunction with the effect of cholesterol-derived metabolites on intracellular mechanisms and cellular plasticity phenomena could provide new approaches to elucidate the triggering factors of carcinogenesis, conditions that could be considered in the development of new therapeutic approaches.

show abstract

High‐density lipoprotein functionality and breast cancer: A potential therapeutic target

Cited by 19 publications

References 107 publications

Revealing the Role of High-Density Lipoprotein in Colorectal Cancer

Revealing the Role of High-Density Lipoprotein in Colorectal Cancer

Low‐Density Lipoproteins, High‐Density Lipoproteins (HDL), and HDL‐Associated Proteins Differentially Modulate Chronic Myelogenous Leukemia Cell Viability

Impact of cholesterol-pathways on breast cancer development, a metabolic landscape

Contact Info

Product

Resources

About